Life Sciences workshops - Valuation from a start-up perspective

Date
07.02.2019 15:00 - 18:30
Location
Switzerland Innovation Park Basel Area AG, Gewerbestrasse 24, 4123 Allschwil
Author
Lea Lindler

The purpose of this workshop is to decrypt the reasons behind using rNPV or VC methodologies to value a product or a Biotech company.

The risk adjusted, net present value (rNPV) method is the standard valuation method used within pharma and biotech companies when valuing assets beyond discovery stage. Well-calibrated the rNPV method is a powerful tool to build, challenge and value the company’s strategy. It also shows how the value of the company develops along reaching milestones. Is it however enough for investors?
 
From an investor’s perspective it is crucial to understand how long it takes before an exit and what is the potential for ROI (Return on Investment). They need to figure out the conditions to harvest their investment as well as to anticipate the multiple later-round investors and incentive packages to key employees that may dilute their stake. Learn the how’s and when’s of using the rNPV method versus the venture capital method.


Register/Details:

Show All

Events

18.03.2019 16:15 - 20:00

62nd SICTIC Investor Day Geneva @CERN

CERN, 1217 Meyrin, Geneva
18 - 24 March 2019

Open Geneva 2019

Canton of Geneva
19.03.2019 17:30

Spark Award ETH

ETH Zurich, Audimax (HG FO 36.1), Main Building, Rämistrasse 101, HG F 33.1, Zürich
Show All

Trainings

05.03.2019 14:00 - 02.04.2019 18:00

Fast Track - Board Academy

EPFL Innovation Park - Lausanne
18.03.2019 18:00 - 21:00

How to Start a Company in Switzerland

startup space, Wiesenstr. 5, Schlieren

Principal

15.03.2019
Editorial

Digital transformation without end

Partners

Contributors

By continuing to use this website you agree with our TERMS AND CONDITIONS